Brazil’s Weight-Loss Drug Market Enters a Price War

Brazil · Corporates

Key Facts

—The cut. Eli Lilly trimmed the price of its weight-loss drug Mounjaro in Brazil by as much as 36 percent through a loyalty program.

—The numbers. A starter pack fell from about R$3,350 ($666) to R$2,250 ($447), with some combinations down by more than R$2,000.

—The trigger. The cut landed days before EMS, a Brazilian drugmaker, launched a cheaper local pen called Ozivy.

—The market. Sales of these pens in Brazil are projected to reach R$15.6bn ($3.1bn) in 2026, a fast-growing and crowded field.

—The catalyst. The patent on semaglutide, the active ingredient in rival Ozempic, expires in Brazil in 2026, opening the door to copies.

—The analyst view. Goldman Sachs said the move makes the competitive picture tougher for drugmaker Hypera than first expected.

A price war has broken out in Brazil’s booming market for the weight-loss drug pens that have swept the world, and the contest could reshape who profits from the craze.

RTAsk Rio TimesAsk about Latin American markets, currencies, and companies — answered from our reporting and live data.Start asking →

The injectable pens known abroad as Ozempic and Mounjaro have become one of the hottest products in pharmacies worldwide. In Brazil, the fight to sell them is turning into a price war.

The opening shot came from Eli Lilly, the American maker of Mounjaro. It cut the drug’s price in Brazil by as much as a third, just as cheaper local rivals prepared to enter the market.

The weight-loss drug discounts, in numbers

The savings are large. A starter pack that cost around three thousand three hundred reais, roughly six hundred and sixty dollars, now sells for about two thousand two hundred and fifty reais, or four hundred and forty-seven dollars.

Some combinations fell even further, with cuts of more than two thousand reais. The reductions come through Lilly’s customer loyalty program and apply both in physical pharmacies and online.

The timing is the real story. The price cut landed only days before a Brazilian company, EMS, rolled out its own cheaper pen, a locally made version of semaglutide called Ozivy.

That local product is far cheaper still, priced at a few hundred reais against the four figures that the branded imports command. The gap is what makes the new arrivals so disruptive.

The stakes are global, not just Brazilian. Mounjaro recently became the world’s best-selling medicine, with quarterly revenue of about eight billion dollars, overtaking a long-dominant cancer drug.

Lilly’s discount is partly a defensive move. The company wants buyers back in official pharmacies, away from compounded copies and illegal imports that have flooded the market.

The scale of that grey market is large. Brazil imported enough raw material for tens of millions of compounded doses in just six months, undercutting the registered products.

Why the patent clock matters

Behind the sudden competition sits a legal milestone. The patent on semaglutide, the active ingredient in Novo Nordisk‘s Ozempic, expires in Brazil during 2026.

Once a patent lapses, local firms can make their own copies. Brazil’s regulator is reviewing a wave of new registrations, a sign that many more cheaper pens are on the way.

There is also a uniquely Brazilian wrinkle. The country’s rules let compounding pharmacies prepare these substances, and that practice has ballooned far beyond its intended scale.

All of this squeezes the makers of branded and premium products from several directions at once. Cheaper copies, compounded versions and grey-market imports are all competing for the same patients.

Who stands to lose

For investors, the question is which companies the price war hurts. One name analysts have flagged is Hypera, a large Brazilian drugmaker active in the same segment.

Goldman Sachs said the Mounjaro cut signals that the competitive environment for Hypera could prove more challenging than the bank had first expected. This is the analyst’s reading, not a forecast of the company’s results.

The logic is that a cheaper Mounjaro, already seen as clinically strong, could pull customers away from rival treatments based on semaglutide. As the price gap narrows, patients may simply trade up.

The rival camp is not standing still. Novo Nordisk, which makes Ozempic, has also trimmed its price, while a Brazilian partner has rolled out a cheaper pen of its own.

With the regulator weighing a stack of new applications, the number of competing pens looks set to keep climbing. More entrants usually mean still lower prices.

For a foreign reader, Brazil is a preview of a global shift. As patents expire and local copies arrive, the eye-watering prices of the weight-loss era are starting to come down.

Frequently Asked Questions

What changed with Mounjaro’s price in Brazil?

Eli Lilly cut the price by as much as 36 percent through a loyalty program. A starter pack fell from about R$3,350 ($666) to R$2,250 ($447), with some combinations down by more than R$2,000.

Why is this happening now?

A Brazilian rival, EMS, has launched a much cheaper local pen, and the patent on semaglutide expires in Brazil in 2026. Together those events are opening the market to far cheaper competition.

Which company could be hurt?

Goldman Sachs flagged Hypera, a large Brazilian drugmaker in the same segment, as facing a tougher competitive picture. That is the bank’s analysis rather than a definitive judgment on the firm’s performance.

The Rio Times · Power Map

See who really holds power in Latin America

Click to open the Power Map →